Gonadorelin
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
A clinic-driven HCG alternative for TRT users who want to preserve testicular signaling: gonadorelin can raise LH and FSH when the pituitary still responds, but the useful read is bounded by labs, fertility endpoints, and pulse-like dosing.
Usually low acute side-effect burden when pulse-dosed, but continuous exposure or the wrong GnRH-family drug can flip the outcome from stimulation to suppression.
A clinic-driven HCG alternative for TRT users who want to preserve testicular signaling: gonadorelin can raise LH and FSH when the pituitary still responds, but the useful read is bounded by labs, fertility endpoints, and pulse-like dosing.
The main risk is mechanism reversal: continuous or overly frequent exposure can suppress LH/FSH instead of stimulating them. Long suppression can also blunt testicular response even when pituitary labs move, and native gonadorelin must not be confused with long-acting GnRH agonist analogs such as triptorelin or leuprolide.
The appeal is full upstream signaling rather than a downstream LH mimic: gonadorelin asks the pituitary to release both LH and FSH, has FDA-approved diagnostic legitimacy, and is usually tolerable at clinic-style SubQ doses. That does not make it stronger than HCG for fertility; it makes it a different tool when HCG access, FSH signaling, or diagnostic axis information matters.
Best-supported for diagnostic stimulation and clinician-managed hypogonadotropic hypogonadism protocols. In TRT-adjunct use, field reports show testicular-size and libido wins, but objective blood-work and fertility confirmation at 100-200 mcg twice weekly remain thin; nonresponse is plausible when pituitary or testicular sensitivity is already blunted.
Never substitute triptorelin or leuprolide for gonadorelin — GnRH agonists cause chemical castration with continuous use, not stimulation.
Intro
Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the 10-amino acid decapeptide produced by the hypothalamus that serves as the master regulator of the reproductive axis.
First isolated and characterized by Andrew Schally, who won the 1977 Nobel Prize in Physiology or Medicine for this work, gonadorelin controls the entire hypothalamic-pituitary-gonadal (HPG) axis through its pulsatile release pattern. When administered in pulsatile fashion — matching the natural 60-120 minute pulse rhythm of hypothalamic GnRH neurons — gonadorelin stimulates anterior pituitary gonadotroph cells to secrete both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then drives testicular testosterone production and Leydig cell function; FSH drives Sertoli cells and spermatogenesis. In its FDA-approved diagnostic form (Factrel, 100 mcg IV), gonadorelin measures pituitary gonadotroph responsiveness. It was previously approved as Lutrepulse for pulsatile pump therapy in hypothalamic amenorrhea and hypogonadotropic hypogonadism (HH), though Lutrepulse was discontinued. In current community use, gonadorelin has become the primary HCG alternative for TRT patients following HCG's price increase and reduced prescribing since 2020. The compound occupies a unique niche: it is the only agent that stimulates the full LH+FSH cascade from the pituitary level, rather than substituting for either downstream hormone.
Observed Effects
In hypogonadotropic hypogonadism (the best-studied clinical application), pulsatile gonadorelin pump therapy achieves testicular volume restoration and spermatogenesis in most patients within 6 months.
Injection protocols achieve comparable outcomes in approximately 14 months. LH and FSH both rise — unlike HCG, which provides only the LH component. In community TRT use, the most commonly reported positive outcomes are testicular size restoration and libido improvement. One well-documented men's-health forum case report describes complete testicular size restoration within 10 days of starting 0.5 mL twice-weekly on a clinically prescribed protocol after 18 months of TRT, with subjective libido described as the strongest the user had experienced. A 2020 men's-health forum experiment by moderator Cataceous combined GnRH with enclomiphene while continuing TRT and HCG; over 7 weeks, LH and FSH rose from approximately 0.1 mIU/mL to 1.0 mIU/mL — a 10x increase — demonstrating that pituitary responsiveness can be partially restored even during ongoing TRT. However, practitioner experience with community dosing protocols (100-200 mcg SubQ twice weekly) yields a more cautious read: experienced practitioners in the community note that blood work confirming effective hormone stimulation at these doses remains rare in the anecdotal record, and that HCG consistently shows more reliable fertility outcomes in direct comparison.
Field Reports
The most documented positive community experience is from men's-health forum user Jda016: prescribed 0.5 mL gonadorelin twice weekly by his TRT clinic after 18 months on TRT.
Within 10 days, testicular size completely returned. Libido was described as stronger than at any prior point. This is the benchmark positive report that circulates in community discussions. men's-health forum moderator Cataceous (2020) conducted a systematic experiment: added GnRH to an ongoing TRT + HCG protocol, with enclomiphene for estrogen feedback blockade. Over 7 weeks, LH and FSH rose from approximately 0.1 mIU/mL to approximately 1.0 mIU/mL, documenting that pituitary responsiveness can be partially restored even during active TRT. Subjective results were described as encouraging. Gabriel Alizaidy, MD, documents a fertility-preserving TRT approach combining minimal-dose testosterone with gonadorelin to maintain axis signaling — the 'R in TRT isn't replacement' philosophy. His context: testosterone at 860 ng/dL on paper but suboptimal in function; started optimization combining low-dose TRT with gonadorelin to avoid full axis suppression. On the contrasting side, experienced practitioners in the community consistently note that users reporting HCG experiences have clear and documentable fertility outcomes with bloodwork, while gonadorelin's community evidence base for fertility preservation specifically remains largely anecdotal and not supported by matched bloodwork.
Community Consensus
Gonadorelin's community adoption is almost entirely cost-driven: HCG price increases since 2020 pushed TRT clinics toward prescribing gonadorelin as the default testicular maintenance agent.
The compound was being prescribed by physicians as early as 2020 (men's-health forum user Ktrt11's doctor-initiated switch), suggesting clinical uptake preceded widespread community awareness. The community is split on efficacy. Positive reports are real and documented — particularly testicular size restoration within 10 days and libido improvement on clinically prescribed twice-weekly protocols. But the practitioner community holds a more skeptical view: experienced coaches and practitioners note that blood work confirming meaningful LH/FSH and testosterone elevation at standard community doses (100-200 mcg SubQ twice weekly) is essentially absent from the anecdotal record. The community framing of gonadorelin as 'the hormonal reset nobody talks about' — a path to preserve natural production rather than replace it — resonates with men who are resistant to lifelong TRT dependency. This framing is partially accurate (gonadorelin maintains the HPG signaling chain) but potentially overstated for the expected magnitude of effect at community doses. A recurring misuse pattern involves men selecting gonadorelin for physique goals — an error the community explicitly flags, as gonadorelin is not a performance compound and is not appropriate for this use. The pulsatile vs continuous distinction is well-understood by informed users but remains a source of confusion for those unfamiliar with the GnRH agonist analog class.
Risks & Monitoring
At community-used doses (100-200 mcg SubQ 2-3x/week), gonadorelin is generally well-tolerated. The most commonly reported adverse effects are: transient injection-site reactions (redness, mild swelling), brief nausea in some users, and transient headache. These effects reflect the short half-life and pulse-nature of the compound — systemic exposure is brief and does not produce the sustained hormone disruption seen with GnRH agonist analogs. The critical adverse effect profile to understand is what happens with non-pulsatile administration. Continuous or very frequent dosing (attempting to 'maintain' gonadorelin levels rather than create pulses) causes pituitary GnRH receptor downregulation and paradoxical suppression of LH and FSH — the opposite of the intended effect. This is the same mechanism used therapeutically with GnRH analogs (leuprolide, triptorelin) for prostate cancer and endometriosis. At community frequencies (twice weekly SubQ), this suppression risk is low because the short half-life ensures each dose is cleared before the next. A separate risk is FSH receptor desensitization at the testicular level: in men with prolonged FSH suppression (from extended AAS cycles or long-term TRT without ancillary support), the Sertoli cell FSH receptors may be downregulated even if gonadorelin successfully raises pituitary FSH — reducing the testicular response despite measurable hormonal improvement. This mechanism explains some cases where gonadorelin 'doesn't work' despite lab evidence of pituitary stimulation.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Establishes whether pituitary is suppressed before starting gonadorelin; monitors response at 4-6 weeks
Key to assessing pituitary response — particularly important for fertility goals since HCG does not raise FSH
Baseline before starting; tracks whether gonadorelin is driving testicular testosterone production
SHBG changes on TRT affect the total/free ratio; free T is the biologically active fraction
Gonadorelin drives testosterone, which aromatizes to E2; monitor for E2 excess, especially with AI co-administration
Affects free testosterone calculation; relevant for interpreting gonadorelin response
Required for any fertility application — documents baseline sperm count, motility, morphology; repeat at 6 months
Elevated prolactin can blunt pituitary LH/FSH response and may explain failure to respond to gonadorelin
Avoid With
Do not combine Gonadorelin with the following. Sorted highest-severity first.
Why:GnRH agonist analogs cause pituitary desensitization and paradoxical gonadotropin suppression with continuous use — the exact opposite of gonadorelin's stimulatory effect. Combining or confusing these compounds can produce chemical castration.
What to do:This is the most critical safety distinction in the GnRH compound class. GnRH agonists are FDA-approved to cause chemical castration for prostate cancer and endometriosis. Never substitute one for the other.
Why:Even gonadorelin itself becomes suppressive if delivered continuously rather than pulsatilely. Attempting to 'maintain levels' by dosing every few hours or via continuous infusion will downregulate GnRH receptors, causing LH/FSH suppression.
What to do:This is a self-stacking conflict. Twice weekly or twice daily dosing maintains pulsatile character; continuous infusion does not.
Why:Gonadorelin drives testosterone which aromatizes to E2. Adding an AI without monitoring can crash E2, causing fatigue, joint pain, mood disruption, and potential cardiovascular risk. AI use should be blood-work guided.
What to do:AI misuse alongside hormonal protocols is a documented cause of HPG disruption in community (see men's-health forum 'A Cautionary Tale').
Protocols By Goal
TRT testicular maintenance (preserve size and function): 100 mcg SubQ twice weekly alongside standard TRT.
Monitor LH, FSH, and total testosterone at 4-6 weeks; if no response, consider dose escalation to 150 mcg or switching to HCG. This is the most common use case in US TRT clinics. Fertility preservation on TRT: 100-150 mcg SubQ twice daily. Expect 9-18 months before semen analysis shows meaningful improvement. If HCG access is available, consider HCG 500-1000 IU EOD instead — stronger clinical evidence base for fertility. Combine with FSH monitoring to confirm pituitary response. HPG axis restart (post-cycle or stopping TRT): Begin within 1-2 weeks of last testosterone dose. Protocol: 100-150 mcg SubQ twice daily for 4-8 weeks alongside standard PCT (SERM + HCG if available). Gonadorelin used here specifically because HCG is unavailable in some states. Diagnostic stimulation test: 100 mcg IV at physician's office. Hypogonadotropic hypogonadism (clinical): pulsatile pump therapy 1-10 mcg IV/90 min. This requires physician management and is outside DIY application. Optimization (male, pre-TRT, suppressed from lifestyle stress or overtraining): 100 mcg SubQ twice weekly for 4-8 weeks as a trial. Monitor LH, FSH, T. If pituitary responds, may avoid TRT initiation.
Dosing Details
Standard TRT-adjunct protocol: 100 mcg SubQ twice weekly. Most US TRT clinics use this as the default testicular maintenance protocol alongside testosterone cypionate or enanthate.
This dose is based on clinical experience rather than RCT data for this specific indication. Fertility-optimized protocol: 100-150 mcg SubQ twice daily (morning and evening), sustained for 9-18 months. Median time to pregnancy in fertility-oriented protocols is approximately 27 months. The twice-daily schedule represents a practical compromise since physiological GnRH pulses occur every 60-90 minutes. Pulsatile pump (clinical only): 1-10 mcg IV every 60-90 minutes via portable pump — the mechanism of Lutrepulse. Achieves spermatogenesis in approximately 6 months in HH patients; faster than SubQ injection protocols but requires medical device use. GnRH stimulation test (diagnostic): 100 mcg IV bolus (Factrel), with LH and FSH measured at 0, 30, and 60 minutes. Normal pituitary response: LH peaks 3-8x baseline, FSH peaks 1.5-3x baseline at 30 minutes. Dose escalation: if testosterone or LH/FSH response is insufficient at 4-6 weeks, escalate by 25-50 mcg per injection. Dose range in community practice: 50-250 mcg per injection, 2-3 times weekly. Start at the lower end and titrate to response rather than starting at maximum dose.
Stacks & Alternatives
The primary co-use pattern — gonadorelin added to TRT to prevent testicular atrophy and preserve fertility potential. Testosterone provides the exogenous androgen; gonadorelin maintains HPG axis signaling.
Complementary mechanisms — gonadorelin stimulates pituitary LH+FSH; HCG acts directly on testes as LH analog. Some protocols use both for enhanced fertility coverage. Cataceous's men's-health forum experiment added GnRH to ongoing HCG+TRT and raised LH/FSH 10x.
The Cataceous protocol (2020): GnRH + enclomiphene while on TRT successfully raised LH/FSH from ~0.1 to ~1.0 mIU/mL over 7 weeks. Enclomiphene blocks hypothalamic E2 negative feedback, amplifying pituitary LH/FSH output. Synergistic for pituitary restart.
Testicular health support during HPG axis manipulation — practitioners document injectable carnitine alongside HCG/gonadorelin protocols to support sperm motility and testicular metabolic health.
FSH-dominant alternative to gonadorelin for direct FSH supplementation. Used in fertility protocols when gonadorelin's indirect FSH stimulation is insufficient. HMG is very expensive; gonadorelin is typically tried first.
Alternatives
Stack Cost
Moderate endocrine-axis tax: gonadorelin is not organ-toxic or androgenic, but it consumes an HPG/fertility lane, requires LH/FSH/testosterone monitoring, and becomes the wrong drug if the user confuses pulsatile native GnRH with suppressive GnRH agonist analogs.
The article frames gonadorelin as an HPG-axis modulator whose benefit depends on restoring LH and FSH signaling rather than bypassing it. It does not create direct androgen suppression when used pulsatilely, but continuous or very frequent dosing reverses the mechanism and can suppress LH/FSH.
The existing recommendedPanels section makes LH, FSH, total testosterone, estradiol, SHBG, and fertility semen analysis central to use. PracticalConsiderations says no LH/FSH response at 6 weeks should trigger dose escalation or a switch to HCG.
Most practical use is fertility or testicular maintenance on TRT. The article distinguishes male TRT adjunct use from female hypothalamic amenorrhea treatment and requires semen analysis for fertility goals.
The stackingConflicts section identifies GnRH agonist analog confusion as a hard stop and cautions against unmanaged aromatase inhibitor co-use. These are mechanism conflicts rather than ordinary side-effect add-ons.
Standard community use is SubQ and usually well tolerated, but the article stresses schedule discipline: twice-weekly or twice-daily dosing preserves pulsatile character, while continuous exposure changes the pharmacology.
- ·Counts as the HPG-axis/fertility-support slot; do not casually add another GnRH-family drug unless the protocol clearly distinguishes native gonadorelin from suppressive agonist analogs.
- ·Do not use continuous or very high-frequency dosing to maintain levels; the evidence indicates that changes gonadorelin from stimulatory to suppressive.
- ·If the goal is fertility, the stack must include semen analysis timing, not just subjective testicular size or libido tracking.
- ·If LH and FSH remain near baseline after 4-6 weeks, treat the protocol as nonresponsive rather than stacking more ancillary compounds blindly.
- ·Aromatase inhibitor decisions should follow estradiol-sensitive and testosterone labs because gonadorelin can raise testosterone substrate for aromatization.
- ·Baseline and follow-up LH, FSH, total testosterone, free testosterone, estradiol-sensitive, SHBG, and prolactin.
- ·Semen analysis at baseline and at 6 months minimum for fertility-oriented protocols.
- ·Schedule discipline around pulse-like dosing, especially when using twice-daily fertility protocols.
- ·Decision tree for nonresponse: dose escalation, evaluation of pituitary/testicular responsiveness, or switch to HCG/rFSH/HMG.
- ·Medication-name verification so gonadorelin is not confused with leuprolide, triptorelin, buserelin, nafarelin, or other suppressive GnRH agonist analogs.
The acute side-effect burden is low, but useful deployment requires understanding the HPG axis, lab response, fertility endpoints, and the difference between native GnRH and suppressive GnRH agonists. That makes it a poor casual first peptide despite tolerable injections.
- ·Using it as a generic libido booster without labs or fertility endpoint.
- ·Long-term TRT or AAS suppression with no plan for semen analysis or HCG/rFSH/HMG backup.
- ·Unable to access follow-up LH/FSH/testosterone testing at 4-6 weeks.
- ·Considering leuprolide, triptorelin, buserelin, or nafarelin as substitutes.
Stopping gonadorelin is not described as causing withdrawal, but the underlying TRT suppression, hypogonadotropic hypogonadism, or fertility problem may return or remain unresolved. Off-ramp difficulty depends on whether it was being used as a casual TRT adjunct or as part of a fertility/restart protocol.
- ·Loss of testicular-maintenance signal on TRT
- ·Fertility plan interruption if semen parameters were still recovering
- ·Need to switch to HCG, rFSH, or HMG if LH/FSH or semen response is inadequate
- ·Misreading persistent low LH/FSH as a drug withdrawal effect rather than nonresponse or underlying pituitary/testicular dysfunction
Follow the article's pulse-dosing logic. Stop continuous exposure, verify LH/FSH/testosterone labs, and do not treat suppressive GnRH agonist analog protocols as interchangeable.
Use baseline and follow-up labs as the article recommends. Escalate dose cautiously or switch to HCG, direct FSH, or HMG when pituitary or testicular receptor response is inadequate.
Treat this as a hard identity check before use. The article says agonist analogs produce the opposite suppressive outcome and should never be substituted for gonadorelin.
Use testosterone and estradiol-sensitive labs before changing AI dosing. The article treats AI co-use as blood-work guided, not automatic.
The article notes FSH receptor desensitization and delayed testicular response after prolonged suppression, so gonadorelin may be too indirect or slow alone.
The article's practical use depends on objective response checks rather than subjective libido or testicular-size reports.
Leuprolide, triptorelin, and related analogs can suppress LH/FSH and create the opposite effect from pulsatile gonadorelin.
Gonadorelin can increase testosterone substrate for aromatization, and unmanaged AI use can crash estradiol.
Practical Setup
The most important practical consideration is verifying pituitary responsiveness before initiating a gonadorelin protocol.
If the pituitary has been suppressed for years (long-term TRT without ancillary support, or post-AAS without HCG), LH and FSH will be near zero at baseline. Gonadorelin can restore pituitary LH/FSH secretion, but testicular FSH receptor sensitivity may also be reduced from prolonged FSH absence — creating a situation where pituitary FSH rises but testicular response is blunted. For long-duration suppression cases, HCG or direct FSH (rFSH/HMG) may produce faster testicular response while the FSH receptor pool recovers. Timing matters for PCT/restart use: waiting 5 or more weeks post-TRT before starting gonadorelin is suboptimal — earlier intervention produces better outcomes when the window for natural axis recovery is still open. For users in states without HCG access, gonadorelin is the available alternative and should be started within 1-2 weeks of last testosterone dose. Protocol adherence is essential: the twice-weekly or twice-daily schedule maintains the pulsatile character of natural GnRH. Missed doses for 1-2 days are tolerable; systematic underdosing or irregular use reduces efficacy. Monitor LH, FSH, and total testosterone at 4-6 weeks to confirm response. No response (LH/FSH still near baseline) at 6 weeks suggests either underdosing, pituitary failure, or testicular receptor insensitivity — escalate dose or switch to HCG. Biomarkers to track: LH, FSH, total testosterone, free testosterone, E2 sensitive, SHBG, prolactin. For fertility goals: semen analysis at baseline and at 6 months minimum.
Mechanism Deep Dive
Gonadorelin is a decapeptide with the sequence pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical to endogenous hypothalamic GnRH.
GnRH neurons in the mediobasal hypothalamus release GnRH in pulses into the hypothalamo-hypophyseal portal vessels. These pulses deliver GnRH to anterior pituitary gonadotroph cells, where it binds the GnRH receptor (GnRHR). GnRHR is a 7-transmembrane G protein-coupled receptor with an unusual architecture: it lacks a C-terminal intracellular tail, which dramatically slows its desensitization and internalization compared to other GPCRs. This structural feature is why native gonadorelin maintains stimulatory activity with pulsatile dosing — the receptor is slow to downregulate. Primary signaling: GnRHR couples to Gq/11 protein, activating phospholipase C (PLC). PLC cleaves PIP2 into IP3 (mobilizes intracellular Ca2+) and DAG (activates PKC). The resulting Ca2+ elevation triggers LH and FSH vesicle fusion and secretion. Secondary pathways include Gs/Gi coupling modulating cAMP and cGMP, and activation of MAPK/ERK1/2, PI3K, NF-kB, and EGR1 — the latter being a transcription factor that drives gonadotropin subunit gene expression. Frequency encoding is critical: slow GnRH pulses (every 90-120 minutes) favor FSH synthesis and secretion; fast pulses (every 30-60 minutes) favor LH. This differential response allows the pituitary to produce two functionally distinct hormones from a single upstream signal based on pulse frequency alone. The mechanism reversal with continuous exposure: sustained GnRH receptor occupancy drives GnRHR phosphorylation → beta-arrestin recruitment → receptor internalization → desensitization. The remaining surface receptors become refractory. LH and FSH secretion drops to castrate levels despite continued GnRH signal — the pharmacological basis for GnRH agonist use in prostate cancer and endometriosis. Kisspeptin (upstream): kisspeptin neurons in the arcuate nucleus project to GnRH neurons and drive the GnRH pulse generator. Gonadorelin bypasses this upstream regulation and acts directly at the pituitary. Half-life: IV ~2-4 minutes; SubQ ~20-60 minutes due to slower absorption. Both are far shorter than any GnRH agonist analog.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Natural GnRH pulses occur every 60-120 minutes, and pulsatile gonadorelin stimulates pituitary LH and FSH secretion.
This is a physiology and mechanism claim; it should not be read as proof that low-frequency community TRT-adjunct injections recreate normal pulse dynamics.
Factrel uses a 100 mcg IV gonadorelin diagnostic dose.
Diagnostic bolus response does not establish chronic TRT-adjunct efficacy.
Pulsatile gonadorelin pump therapy achieves testicular volume restoration and spermatogenesis in most hypogonadotropic hypogonadism patients within 6 months.
This endpoint is specific to true HH treatment and should not be transferred directly to standard TRT clinic dosing.
Injection protocols achieve comparable fertility outcomes in approximately 14 months.
The article does not provide the study size or exact protocol, so transfer to casual TRT-adjunct use should remain cautious.
One men's-health forum case reported complete testicular size restoration within 10 days of starting 0.5 mL twice-weekly gonadorelin after 18 months of TRT.
This is a single anecdote with subjective reporting and should not be generalized as expected response time.
A 2020 men's-health forum experiment raised LH and FSH from approximately 0.1 mIU/mL to 1.0 mIU/mL over 7 weeks while combining GnRH with enclomiphene during ongoing TRT and HCG.
The 10x lab increase is confounded by concurrent enclomiphene, TRT, and HCG and should not be attributed to gonadorelin alone.
Standard TRT-adjunct protocol is 100 mcg SubQ twice weekly.
The article states this dosing is based on clinical experience rather than RCT data for the TRT-adjunct indication.
Fertility-optimized protocol is 100-150 mcg SubQ twice daily for 9-18 months, with median time to pregnancy approximately 27 months.
The article does not provide study size or year; the long time-to-pregnancy should not be generalized to users without diagnosed fertility impairment.
Pulsatile pump therapy uses 1-10 mcg IV every 60-90 minutes and achieves spermatogenesis in approximately 6 months in HH patients.
Device-based pulsatile treatment is not the same exposure pattern as twice-weekly community SubQ dosing.
GnRH stimulation testing uses 100 mcg IV with LH/FSH measured at 0, 30, and 60 minutes; normal response is LH 3-8x baseline and FSH 1.5-3x baseline at 30 minutes.
Diagnostic response thresholds test pituitary reserve and do not predict fertility restoration by themselves.
Dose escalation is 25-50 mcg per injection if testosterone or LH/FSH response is insufficient at 4-6 weeks; community practice range is 50-250 mcg per injection, 2-3 times weekly.
These are practice-pattern dosing ranges, not controlled efficacy thresholds.
Monitor LH, FSH, and total testosterone at 4-6 weeks; no response by 6 weeks suggests underdosing, pituitary failure, or testicular receptor insensitivity.
This is an operational monitoring rule from the article, not a population-derived efficacy statistic.
For fertility goals, semen analysis should be done at baseline and at 6 months minimum.
Semen-analysis timing is a monitoring schedule and should not be read as a guarantee that sperm parameters normalize by 6 months.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.